Back

PCSK9 inhibitors: what we know, what we should have understood, and what is to come

European Heart Journal

23 July 2019
Organised by: Logo
Read full article
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention BASIC SCIENCE

Contributors

Marc S Sabatine
Marc S Sabatine

Author

Brigham and Women's Hospital, Harvard Medical School Boston , United States of America

You may be interested in
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources